John A Connolly, MD
Urology · Burlingame
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
Offices
4 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Connolly’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A56059 · Current
Licensed to practise in California · since 1996 · expires 2027-08-31 · National University of Ireland University College at Dublin.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$432,269
Medicare paid this office $432,269 for 1,306 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 1,204 | $221,912 | $108 |
| Diagnostic exam of bladder and urethra using an endoscope | 144 | $49,094 | $244 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 32 | $28,541 | None |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 1,050 | $22,939 | $14 |
| New patient visit (45+ min) | 86 | $12,433 | $145 |
See all 26 services
| Return visit (30+ min) | 1,204 | $221,912 | $108 |
| Diagnostic exam of bladder and urethra using an endoscope | 144 | $49,094 | $244 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 32 | $28,541 | None |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 1,050 | $22,939 | $14 |
| New patient visit (45+ min) | 86 | $12,433 | $145 |
| Short return visit (20+ min) | 112 | $10,981 | $80 |
| Complete ultrasound scan of pelvis | 59 | $6,416 | $109 |
| Ultrasound measurement of bladder capacity after voiding | 419 | $5,980 | $11 |
| Dilation of urethra using an endoscope | 18 | $5,949 | $331 |
| Biopsy of prostate gland | 21 | $4,642 | $221 |
| Insertion of lower leg neurostimulator electrode | 13 | $4,531 | $119 |
| Injection of drug or substance under skin or into muscle | 62 | $4,270 | $13 |
| Simple insertion of temporary bladder tube | 13 | $3,608 | $57 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $3,547 | $322 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $3,365 | $102 |
| Long return visit (40+ min) | 19 | $3,028 | $159 |
| Automated urinalysis test | 891 | $2,734 | $2 |
| Telephone medical discussion with physician, 11-20 minutes | 25 | $2,198 | $79 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,195 | $100 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 30 | $1,748 | $37 |
| Simple bladder irrigation and/or instillation | 15 | $1,402 | $78 |
| Ultrasonic guidance for needle placement | 20 | $1,157 | $58 |
| Manual urinalysis test with examination using microscope, automated | 143 | $516 | $3 |
| Imaging of urinary tract following injection of a contrast agent | 11 | $238 | $22 |
| Injection, garamycin, gentamicin, up to 80 mg | 21 | $45 | None |
| Injection, testosterone cypionate, 1 mg | 42 | $21 | None |
Procedures Medicare counted
| Prostate resection | 1-10 | None |
Who their Medicare patients are
1,306 Original Medicare patients in 2024. Average age 79 · Under 65 1% · 85 and older 23% · Women 25% · Also on Medicaid 2% · Health risk score 1.15. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 74% · Cancer 31% · Coronary heart disease 28% · Atrial fibrillation 25% · Diabetes 23% · Chronic kidney disease 23% · Heart failure 16% · Depression 11% · COPD 10% · Dementia 6% · Stroke 6%.
The office billed $1,877,439, Medicare allowed $587,751 and paid $432,269; for 120,969 services of 59 kinds; $30,633 of it was for drugs given in the office and $401,636 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,306 | 120,969 | 79 | 1.15 | $1,877,439 | $432,269 |
| 2023 | 1,315 | 100,891 | 79 | 1.10 | $1,845,571 | $439,879 |
| 2022 | 1,323 | 30,027 | 79 | 1.08 | $1,961,544 | $462,921 |
| 2021 | 1,298 | 22,492 | 78 | 1.09 | $1,889,885 | $448,770 |
| 2020 | 1,279 | 37,393 | 78 | 1.16 | $1,573,730 | $372,006 |
| 2019 | 1,250 | 5,910 | 78 | 1.16 | $1,405,044 | $402,490 |
| 2018 | 1,245 | 6,499 | 78 | 1.22 | $1,455,221 | $392,448 |
| 2017 | 1,259 | 7,163 | 78 | 1.18 | $1,640,574 | $464,616 |
| 2016 | 1,264 | 6,740 | 78 | 1.24 | $1,501,292 | $432,087 |
| 2015 | 1,212 | 5,844 | 78 | 1.17 | $1,124,860 | $357,767 |
| 2014 | 1,176 | 6,290 | 78 | 1.08 | $1,056,324 | $382,393 |
| 2013 | 1,087 | 5,872 | 78 | 1.07 | $1,023,596 | $376,684 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 25 services
| Return visit (30+ min) | 1,159 | $208,638 | $109 |
| Diagnostic exam of bladder and urethra using an endoscope | 143 | $51,247 | $245 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 40 | $36,248 | None |
| Short return visit (20+ min) | 214 | $21,448 | $77 |
| New patient visit (45+ min) | 107 | $15,526 | $145 |
| Complete ultrasound scan of pelvis | 80 | $8,536 | $107 |
| Biopsy of prostate gland | 32 | $7,804 | $236 |
| Ultrasound measurement of bladder capacity after voiding | 389 | $4,947 | $11 |
| Simple insertion of temporary bladder tube | 19 | $4,858 | $56 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 13 | $4,560 | $326 |
| Long return visit (40+ min) | 25 | $4,192 | $168 |
| Telephone medical discussion with physician, 11-20 minutes | 45 | $3,940 | $74 |
| Injection of drug or substance under skin or into muscle | 72 | $3,763 | $12 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,736 | $67 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,354 | $112 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 42 | $2,322 | $35 |
| Automated urinalysis test | 707 | $2,013 | $2 |
| Ultrasonic guidance for needle placement | 32 | $1,928 | $58 |
| Telephone medical discussion with physician, 5-10 minutes | 42 | $1,813 | $43 |
| Simple bladder irrigation and/or instillation | 12 | $1,490 | $78 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,333 | $111 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $879 | $68 |
| Manual urinalysis test with examination using microscope, automated | 138 | $479 | $3 |
| Injection, testosterone cypionate, 1 mg | 47 | $124 | None |
| Injection, tobramycin sulfate, up to 80 mg | 28 | $56 | None |
2022: 30 services
| Return visit (30+ min) | 1,144 | $199,340 | $107 |
| Diagnostic exam of bladder and urethra using an endoscope | 163 | $55,123 | $245 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 45 | $38,795 | None |
| Short return visit (20+ min) | 240 | $25,260 | $76 |
| New patient visit (45+ min) | 101 | $13,322 | $132 |
| Insertion of needle or tube into prostate for radiation therapy | 13 | $9,188 | $707 |
| Biopsy of prostate gland | 37 | $8,918 | $241 |
| Complete ultrasound scan of pelvis | 82 | $8,745 | $105 |
| Instillation of anti-cancer drug into bladder | 16 | $7,043 | $85 |
| Simple insertion of temporary bladder tube | 27 | $5,817 | $59 |
| Dilation of urethra using an endoscope | 13 | $5,642 | $332 |
| Long return visit (40+ min) | 29 | $5,060 | $169 |
| Injection of drug or substance under skin or into muscle | 86 | $4,838 | $13 |
| Telephone medical discussion with physician, 11-20 minutes | 58 | $4,690 | $71 |
| Ultrasound measurement of bladder capacity after voiding | 323 | $4,028 | $10 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 11 | $2,730 | $248 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | $2,428 | $97 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 45 | $2,366 | $34 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,174 | $121 |
| Ultrasonic guidance for needle placement | 37 | $2,093 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,725 | $64 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $1,649 | None |
| Simple bladder irrigation and/or instillation | 14 | $1,400 | $74 |
| Initial dilation of urethra in female | 23 | $1,299 | $52 |
| Automated urinalysis test | 416 | $1,178 | $2 |
| Ultrasonic guidance for administration of radiation therapy | 13 | $798 | $61 |
| Manual urinalysis test with examination using microscope, automated | 67 | $247 | $3 |
| Injection procedure for imaging of bladder during voiding | 12 | $233 | $19 |
| Injection, testosterone cypionate, 1 mg | 36 | $73 | None |
| Injection, garamycin, gentamicin, up to 80 mg | 35 | $62 | None |
2021: 29 services
| Return visit (30+ min) | 1,148 | $202,597 | $107 |
| Diagnostic exam of bladder and urethra using an endoscope | 163 | $55,190 | $235 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 45 | $43,666 | None |
| Short return visit (20+ min) | 160 | $15,445 | $78 |
| New patient visit (45+ min) | 117 | $15,136 | $129 |
| Complete ultrasound scan of pelvis | 111 | $12,337 | $110 |
| Insertion of needle or tube into prostate for radiation therapy | 12 | $8,482 | $707 |
| Dilation of urethra using an endoscope | 20 | $7,919 | $330 |
| Instillation of anti-cancer drug into bladder | 14 | $5,649 | $88 |
| Biopsy of prostate gland | 25 | $5,557 | $222 |
| Long return visit (40+ min) | 33 | $5,020 | $148 |
| Injection of drug or substance under skin or into muscle | 79 | $4,865 | $13 |
| Simple insertion of temporary bladder tube | 17 | $4,072 | $59 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $3,682 | $307 |
| Telephone medical discussion with physician, 21-30 minutes | 28 | $3,369 | $99 |
| Telephone medical discussion with physician, 11-20 minutes | 39 | $2,992 | $68 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 45 | $2,507 | $33 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,440 | $64 |
| Automated urinalysis test | 704 | $2,036 | $2 |
| Ultrasound measurement of bladder capacity after voiding | 163 | $1,851 | $10 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $1,517 | None |
| Ultrasonic guidance for needle placement | 25 | $1,419 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,280 | $116 |
| New patient visit (30+ min) | 11 | $809 | $74 |
| Ultrasonic guidance for administration of radiation therapy | 12 | $739 | $62 |
| Manual urinalysis test with examination using microscope, automated | 83 | $323 | $3 |
| Injection procedure for imaging of bladder during voiding | 11 | $215 | $20 |
| Injection, garamycin, gentamicin, up to 80 mg | 27 | $47 | None |
| Injection, testosterone cypionate, 1 mg | 31 | $38 | None |
2020: 28 services
| Return visit (30+ min) | 940 | $117,341 | $95 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 51 | $51,001 | None |
| New patient visit (45+ min) | 253 | $37,230 | $147 |
| Diagnostic exam of bladder and urethra using an endoscope | 133 | $36,911 | $211 |
| Short return visit (20+ min) | 312 | $29,657 | $68 |
| Complete ultrasound scan of pelvis | 82 | $9,041 | $109 |
| Insertion of needle or tube into prostate for radiation therapy | 11 | $7,841 | $713 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $5,841 | $64 |
| Biopsy of prostate gland | 23 | $5,527 | $240 |
| Telephone medical discussion with physician, 11-20 minutes | 52 | $3,871 | $68 |
| Simple insertion of temporary bladder tube | 21 | $3,551 | $61 |
| Injection of drug or substance under skin or into muscle | 69 | $3,497 | $14 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,880 | $125 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 50 | $2,372 | $32 |
| Automated urinalysis test | 799 | $2,326 | $2 |
| Long return visit (40+ min) | 16 | $2,094 | $131 |
| New patient visit (30+ min) | 19 | $1,721 | $91 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | $1,341 | $103 |
| Ultrasonic guidance for needle placement | 22 | $1,231 | $56 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,091 | $91 |
| Ultrasound measurement of bladder capacity after voiding | 81 | $973 | $11 |
| Manual urinalysis test with examination using microscope, automated | 218 | $731 | $3 |
| Ultrasonic guidance for administration of radiation therapy | 11 | $688 | $63 |
| Limited ultrasound scan of pelvis | 12 | $568 | $47 |
| Injection, testosterone cypionate, 1 mg | 32 | $299 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 21 | $221 | $10 |
| Injection procedure for imaging of bladder during voiding | 11 | $221 | $20 |
| Injection, garamycin, gentamicin, up to 80 mg | 24 | $47 | None |
2019: 26 services
| Return visit (30+ min) | 828 | $107,198 | $88 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 58 | $63,609 | None |
| Long return visit (40+ min) | 299 | $45,634 | $125 |
| Diagnostic exam of bladder and urethra using an endoscope | 123 | $28,649 | $168 |
| Short return visit (20+ min) | 220 | $20,770 | $64 |
| New patient visit (45+ min) | 137 | $19,070 | $139 |
| Complete ultrasound scan behind abdominal cavity | 157 | $18,461 | $107 |
| Insertion of needle or tube into prostate for radiation therapy | 20 | $13,331 | $667 |
| Limited ultrasound scan of pelvis | 305 | $13,191 | $39 |
| Manual urinalysis test with examination using microscope, non-automated | 1,106 | $7,796 | $4 |
| Biopsy of prostate gland | 31 | $7,475 | $241 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,551 | $179 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 85 | $4,000 | $21 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 12 | $3,910 | $326 |
| Ultrasound scan of pelvic region through rectum | 31 | $3,768 | $122 |
| Dilation of urethra using an endoscope | 13 | $3,652 | $281 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $3,092 | $64 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 56 | $2,696 | $31 |
| Insertion of device into abdomen with pressure and urine flow rate study | 12 | $1,686 | $140 |
| Ultrasonic guidance for needle placement | 23 | $1,254 | $55 |
| Ultrasonic guidance for administration of radiation therapy | 20 | $1,223 | $61 |
| Ultrasound measurement of bladder capacity after voiding | 74 | $926 | $12 |
| Injection procedure for imaging of bladder during voiding | 20 | $398 | $20 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 12 | $391 | $33 |
| Electronic assessment of bladder emptying | 12 | $82 | $7 |
| Urinalysis, manual test | 16 | $65 | $3 |
2018: 21 services
| Return visit (30+ min) | 979 | $131,845 | $85 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 48 | $51,554 | None |
| Limited ultrasound scan of pelvis | 664 | $36,230 | $41 |
| Diagnostic exam of bladder and urethra using an endoscope | 121 | $21,815 | $136 |
| Long return visit (40+ min) | 94 | $19,493 | $119 |
| Short return visit (20+ min) | 206 | $18,975 | $60 |
| Complete ultrasound scan behind abdominal cavity | 152 | $18,059 | $103 |
| New patient visit (45+ min) | 126 | $16,563 | $131 |
| Manual urinalysis test with examination using microscope, non-automated | 1,106 | $8,138 | $4 |
| Biopsy of prostate gland | 28 | $6,409 | $229 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 13 | $3,909 | $301 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,729 | $162 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 70 | $3,078 | $19 |
| Dilation of urethra using an endoscope | 11 | $2,842 | $237 |
| Ultrasound scan of pelvic region through rectum | 26 | $2,217 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $2,133 | $63 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 47 | $2,133 | $30 |
| Insertion of device into abdomen with pressure and urine flow rate study | 13 | $1,438 | $111 |
| Ultrasound measurement of bladder capacity after voiding | 71 | $1,270 | $15 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 13 | $423 | $33 |
| Electronic assessment of bladder emptying | 13 | $96 | $7 |
2017: 28 services
| Return visit (30+ min) | 949 | $143,575 | $90 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 50 | $60,857 | None |
| Limited ultrasound scan of pelvis | 677 | $40,068 | $45 |
| Diagnostic exam of bladder and urethra using an endoscope | 145 | $27,668 | $147 |
| New patient visit (45+ min) | 176 | $24,270 | $138 |
| Long return visit (40+ min) | 105 | $23,990 | $130 |
| Short return visit (20+ min) | 221 | $21,780 | $64 |
| Complete ultrasound scan behind abdominal cavity | 167 | $20,085 | $107 |
| Insertion of needle or tube into prostate for radiation therapy | 14 | $9,682 | $692 |
| Manual urinalysis test with examination using microscope, non-automated | 1,117 | $9,608 | $4 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 26 | $8,140 | $313 |
| Bcg (intravesical) per instillation | 12 | $8,067 | None |
| Biopsy of prostate gland | 32 | $7,681 | $240 |
| Instillation of anti-cancer drug into bladder | 15 | $7,085 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,329 | $180 |
| Dilation of urethra using an endoscope | 15 | $3,796 | $237 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 12 | $3,117 | $260 |
| Ultrasound scan of pelvic region through rectum | 32 | $3,085 | $93 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 50 | $2,998 | $33 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 76 | $2,993 | $18 |
| Insertion of device into abdomen with pressure and urine flow rate study | 26 | $2,859 | $110 |
| Ultrasound measurement of bladder capacity after voiding | 91 | $1,931 | $19 |
| Ultrasound scan of prostate through rectum | 11 | $1,878 | $171 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,417 | $64 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 26 | $874 | $34 |
| Ultrasonic guidance for administration of radiation therapy | 14 | $848 | $61 |
| Injection procedure for imaging of bladder during voiding | 14 | $278 | $20 |
| Electronic assessment of bladder emptying | 27 | $221 | $8 |
2016: 25 services
| Return visit (30+ min) | 910 | $125,823 | $88 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 44 | $51,676 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 151 | $36,559 | $173 |
| Limited ultrasound scan of pelvis | 550 | $28,828 | $43 |
| New patient visit (45+ min) | 166 | $23,359 | $141 |
| Short return visit (20+ min) | 220 | $20,746 | $60 |
| Complete ultrasound scan behind abdominal cavity | 153 | $19,259 | $104 |
| Long return visit (40+ min) | 86 | $17,267 | $124 |
| Manual urinalysis test with examination using microscope, non-automated | 1,121 | $9,376 | $4 |
| Instillation of anti-cancer drug into bladder | 14 | $9,164 | $96 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 29 | $8,568 | $295 |
| Bcg (intravesical) per instillation | 11 | $7,745 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,657 | $177 |
| New patient visit (60+ min) | 28 | $4,510 | $161 |
| Biopsy of prostate gland | 22 | $4,484 | $204 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 134 | $4,131 | $17 |
| Insertion of device into abdomen with pressure and urine flow rate study | 29 | $3,131 | $108 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 29 | $2,664 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,270 | $63 |
| Ultrasound scan of pelvic region through rectum | 23 | $2,257 | $94 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 40 | $1,938 | $32 |
| Ultrasound measurement of bladder capacity after voiding | 89 | $1,833 | $19 |
| Insertion of stent in ureter using an endoscope | 13 | $1,180 | $84 |
| Ultrasonic guidance for needle placement | 18 | $1,047 | $58 |
| Electronic assessment of bladder emptying | 30 | $234 | $8 |
2015: 22 services
| Return visit (30+ min) | 834 | $111,989 | $90 |
| Diagnostic exam of bladder and urethra using an endoscope | 147 | $35,307 | $176 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 31 | $27,847 | None |
| Limited ultrasound scan of pelvis | 475 | $25,741 | $45 |
| Long return visit (40+ min) | 85 | $16,263 | $123 |
| New patient visit (60+ min) | 90 | $16,150 | $179 |
| Short return visit (20+ min) | 180 | $15,951 | $61 |
| Complete ultrasound scan behind abdominal cavity | 127 | $15,340 | $105 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 34 | $10,652 | $313 |
| Manual urinalysis test with examination using microscope, non-automated | 1,047 | $8,220 | $4 |
| Instillation of anti-cancer drug into bladder | 14 | $7,541 | $95 |
| New patient visit (45+ min) | 51 | $7,268 | $143 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 180 | $6,864 | $18 |
| Dilation of urethra using an endoscope | 16 | $3,849 | $241 |
| Insertion of device into abdomen with pressure and urine flow rate study | 33 | $3,705 | $112 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 33 | $3,155 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,867 | $179 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $2,178 | $64 |
| Complete ultrasound scan of pelvis | 15 | $1,679 | $112 |
| Ultrasound measurement of bladder capacity after voiding | 69 | $1,532 | $20 |
| Initial dilation of urethra in female | 15 | $1,024 | $68 |
| Electronic assessment of bladder emptying | 34 | $267 | $8 |
2014: 23 services
| Return visit (30+ min) | 870 | $120,945 | $90 |
| Diagnostic exam of bladder and urethra using an endoscope | 137 | $35,708 | $182 |
| Short return visit (20+ min) | 330 | $31,001 | $62 |
| Limited ultrasound scan of pelvis | 450 | $28,624 | $52 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 27 | $24,898 | None |
| New patient visit (45+ min) | 113 | $15,186 | $134 |
| Complete ultrasound scan behind abdominal cavity | 97 | $13,580 | $129 |
| Long return visit (40+ min) | 61 | $9,398 | $132 |
| New patient visit (60+ min) | 49 | $9,092 | $186 |
| Manual urinalysis test with examination using microscope, non-automated | 1,031 | $8,745 | $4 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 26 | $8,164 | $314 |
| Instillation of anti-cancer drug into bladder | 13 | $8,097 | $99 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 175 | $7,546 | $17 |
| Dilation of urethra using an endoscope | 24 | $6,116 | $235 |
| Simple insertion of temporary bladder tube | 12 | $4,371 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,601 | $180 |
| Insertion of device into abdomen with pressure and urine flow rate study | 26 | $2,888 | $111 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 26 | $2,468 | $95 |
| Initial dilation of urethra in female | 27 | $2,301 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,879 | $63 |
| Ultrasound measurement of bladder capacity after voiding | 77 | $1,669 | $20 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $883 | $30 |
| Electronic assessment of bladder emptying | 26 | $195 | $7 |
2013: 30 services
| Return visit (30+ min) | 755 | $97,005 | $88 |
| Short return visit (20+ min) | 321 | $41,495 | $64 |
| Limited ultrasound scan of pelvis | 343 | $31,799 | $82 |
| Diagnostic exam of bladder and urethra using an endoscope | 118 | $30,435 | $180 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 34 | $28,173 | None |
| New patient visit (45+ min) | 109 | $15,719 | $144 |
| Complete ultrasound scan behind abdominal cavity | 66 | $10,318 | $134 |
| Instillation of anti-cancer drug into bladder | 18 | $8,591 | $99 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 155 | $8,343 | $18 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 25 | $8,337 | $321 |
| Manual urinalysis test with examination using microscope, non-automated | 907 | $7,575 | $4 |
| Simple insertion of temporary bladder tube | 18 | $6,844 | $66 |
| Initial dilation of urethra in female | 38 | $5,814 | $66 |
| Dilation of urethra using an endoscope | 23 | $5,756 | $250 |
| Bcg (intravesical) per instillation | 11 | $5,640 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,680 | $167 |
| Insertion of device into abdomen with pressure and urine flow rate study | 25 | $2,832 | $109 |
| Ultrasonic guidance for needle placement | 13 | $2,807 | $216 |
| Long return visit (40+ min) | 19 | $2,680 | $128 |
| Biopsy of prostate gland | 13 | $2,671 | $205 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 26 | $2,610 | $97 |
| New patient visit (60+ min) | 12 | $2,237 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $2,064 | $63 |
| Protein test for diagnosis and monitoring of bladder cancer | 72 | $1,861 | $22 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 34 | $1,306 | $30 |
| Ultrasound measurement of bladder capacity after voiding | 60 | $1,275 | $19 |
| Ultrasound scan of pelvic region through rectum | 13 | $1,007 | $72 |
| New patient visit (30+ min) | 12 | $821 | $68 |
| Short return visit | 15 | $681 | $40 |
| Electronic assessment of bladder emptying | 26 | $200 | $7 |
Drugs they prescribed that Part D paid
$325,054
Pharmacies billed $325,054 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
4,285 generic and fewer than 11 brand-name prescriptions · $325,054 in drug cost · 810 antibiotic prescriptions to 313 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 193 | $182,220 | $944 |
| Tamsulosin | 1,351 | $29,096 | $22 |
| Finasteride | 998 | $17,478 | $18 |
| Methenamine Hippurate | 71 | $8,191 | $115 |
| Darifenacin Er | 19 | $8,088 | $426 |
See all 35 drugs
| Myrbetriq | 193 | $182,220 | $944 |
| Tamsulosin | 1,351 | $29,096 | $22 |
| Finasteride | 998 | $17,478 | $18 |
| Methenamine Hippurate | 71 | $8,191 | $115 |
| Darifenacin Er | 19 | $8,088 | $426 |
| Tadalafil | 43 | $7,503 | $174 |
| Estradiol | 116 | $7,317 | $63 |
| Silodosin | 53 | $7,281 | $137 |
| Trospium Chloride Er | 28 | $6,039 | $216 |
| Testosterone Cypionate | 160 | $5,676 | $35 |
| Premarin | 13 | $5,579 | $429 |
| Trospium Chloride | 92 | $5,075 | $55 |
| Cephalexin | 376 | $4,429 | $12 |
| Alfuzosin Hcl Er | 107 | $3,028 | $28 |
| Potassium Citrate Er | 32 | $2,666 | $83 |
| Nitrofurantoin | 64 | $2,622 | $41 |
| Testosterone | 54 | $2,429 | $45 |
| Dutasteride | 44 | $1,959 | $45 |
| Solifenacin | 26 | $1,737 | $67 |
| Tolterodine Tartrate Er | 13 | $1,664 | $128 |
| Oxybutynin Chloride Er | 39 | $1,168 | $30 |
| Amoxicillin-Clavulanate Potass | 176 | $1,124 | $6 |
| Bethanechol Chloride | 12 | $599 | $50 |
| Sildenafil Citrate | 35 | $428 | $12 |
| Allopurinol | 21 | $351 | $17 |
| Sulfamethoxazole-Trimethoprim | 58 | $346 | $6 |
| Nitrofurantoin Mono-Macro | 27 | $329 | $12 |
| Doxycycline Hyclate | 20 | $269 | $13 |
| Nystatin | 43 | $264 | $6 |
| Amitriptyline | 18 | $261 | $15 |
| Imipramine | 11 | $227 | $21 |
| Ciprofloxacin | 45 | $154 | $3 |
| Levofloxacin | 34 | $125 | $4 |
| Fluconazole | 18 | $52 | $3 |
| Terazosin | 18 | $48 | $3 |
Year by year
| 2024 | 4,507 | 961 | None | None | $325,054 |
| 2023 | 4,253 | 907 | None | None | $348,104 |
| 2022 | 4,089 | 888 | 0% (13) | None | $333,368 |
| 2021 | 3,947 | 855 | None | None | $288,061 |
| 2020 | 3,329 | 786 | None | None | $206,970 |
| 2019 | 3,129 | 642 | None | None | $252,637 |
| 2018 | 3,486 | 684 | None | 12% | $282,510 |
| 2017 | 3,563 | 702 | None | None | $258,548 |
| 2016 | 3,048 | 626 | 1% (17) | None | $209,246 |
| 2015 | 2,451 | 516 | 0% (11) | None | $167,624 |
| 2014 | 2,226 | 484 | 1% (25) | None | $148,223 |
| 2013 | 2,184 | 473 | 1% (12) | None | $141,735 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 37 drugs
| Myrbetriq | 176 | $172,249 | $979 |
| Tamsulosin | 1,236 | $32,096 | $26 |
| Finasteride | 968 | $17,574 | $18 |
| Methenamine Hippurate | 83 | $15,953 | $192 |
| Darifenacin Er | 15 | $9,855 | $657 |
| Testosterone | 80 | $8,826 | $110 |
| Estradiol | 96 | $8,773 | $91 |
| Silodosin | 47 | $7,918 | $168 |
| Premarin | 15 | $7,125 | $475 |
| Trospium Chloride Er | 27 | $7,039 | $261 |
| Cephalexin | 304 | $4,906 | $16 |
| Testosterone Cypionate | 132 | $4,769 | $36 |
| Trospium Chloride | 69 | $4,487 | $65 |
| Nitrofurantoin | 80 | $4,279 | $53 |
| Dutasteride | 51 | $4,188 | $82 |
| Solifenacin | 51 | $3,760 | $74 |
| Potassium Citrate Er | 31 | $3,576 | $115 |
| Tadalafil | 28 | $3,361 | $120 |
| Alfuzosin Hcl Er | 77 | $2,400 | $31 |
| Oxybutynin Chloride Er | 51 | $2,259 | $44 |
| Tolterodine Tartrate Er | 14 | $1,919 | $137 |
| Amoxicillin-Clavulanate Potass | 135 | $1,105 | $8 |
| Bethanechol Chloride | 19 | $965 | $51 |
| Nitrofurantoin Mono-Macro | 40 | $701 | $18 |
| Oxybutynin Chloride | 14 | $597 | $43 |
| Allopurinol | 22 | $456 | $21 |
| Hydroxyzine | 18 | $410 | $23 |
| Amitriptyline | 21 | $403 | $19 |
| Sulfamethoxazole-Trimethoprim | 77 | $337 | $4 |
| Sildenafil Citrate | 44 | $261 | $6 |
| Terazosin | 15 | $258 | $17 |
| Ciprofloxacin | 36 | $224 | $6 |
| Nystatin | 28 | $217 | $8 |
| Doxycycline Hyclate | 11 | $199 | $18 |
| Nystop | 12 | $171 | $14 |
| Levofloxacin | 32 | $116 | $4 |
| Fluconazole | 12 | $29 | $2 |
2022: 36 drugs
| Myrbetriq | 165 | $151,766 | $920 |
| Tamsulosin | 1,217 | $30,397 | $25 |
| Finasteride | 896 | $19,008 | $21 |
| Methenamine Hippurate | 74 | $13,575 | $183 |
| Darifenacin Er | 19 | $11,948 | $629 |
| Estradiol | 89 | $8,623 | $97 |
| Trospium Chloride Er | 31 | $8,501 | $274 |
| Solifenacin | 45 | $7,102 | $158 |
| Premarin | 15 | $6,610 | $441 |
| Testosterone Cypionate | 141 | $6,505 | $46 |
| Trospium Chloride | 74 | $5,838 | $79 |
| Dutasteride | 60 | $5,751 | $96 |
| Nitrofurantoin | 87 | $5,660 | $65 |
| Silodosin | 36 | $5,560 | $154 |
| Potassium Citrate Er | 31 | $5,032 | $162 |
| Cephalexin | 314 | $4,561 | $15 |
| Testosterone | 50 | $4,539 | $91 |
| Oxybutynin Chloride Er | 74 | $3,454 | $47 |
| Alfuzosin Hcl Er | 84 | $2,650 | $32 |
| Tolterodine Tartrate Er | 14 | $2,118 | $151 |
| Bethanechol Chloride | 16 | $1,028 | $64 |
| Nitrofurantoin Mono-Macro | 48 | $973 | $20 |
| Amoxicillin-Clavulanate Potass | 79 | $830 | $11 |
| Oxybutynin Chloride | 13 | $699 | $54 |
| Tadalafil | 19 | $695 | $37 |
| Bicalutamide | 17 | $619 | $36 |
| Terazosin | 22 | $529 | $24 |
| Sulfamethoxazole-Trimethoprim | 111 | $489 | $4 |
| Amitriptyline | 18 | $394 | $22 |
| Hydroxyzine | 17 | $337 | $20 |
| Ciprofloxacin | 31 | $290 | $9 |
| Allopurinol | 13 | $209 | $16 |
| Sildenafil Citrate | 16 | $207 | $13 |
| Levofloxacin | 32 | $149 | $5 |
| Nystatin | 11 | $134 | $12 |
| Hydrocodone-Acetaminophen | 12 | $108 | $9 |
2021: 35 drugs
| Myrbetriq | 104 | $84,802 | $815 |
| Tamsulosin | 1,179 | $29,557 | $25 |
| Finasteride | 891 | $22,800 | $26 |
| Darifenacin Er | 36 | $14,435 | $401 |
| Testosterone | 57 | $12,996 | $228 |
| Premarin | 26 | $10,725 | $412 |
| Methenamine Hippurate | 47 | $9,940 | $211 |
| Potassium Citrate Er | 40 | $8,748 | $219 |
| Estradiol | 87 | $8,684 | $100 |
| Solifenacin | 54 | $6,942 | $129 |
| Testosterone Cypionate | 120 | $6,638 | $55 |
| Trospium Chloride Er | 20 | $6,543 | $327 |
| Dutasteride | 58 | $5,307 | $92 |
| Silodosin | 32 | $5,122 | $160 |
| Nitrofurantoin | 91 | $5,001 | $55 |
| Tadalafil | 40 | $5,000 | $125 |
| Cephalexin | 291 | $4,310 | $15 |
| Trospium Chloride | 36 | $3,552 | $99 |
| Oxybutynin Chloride Er | 75 | $3,374 | $45 |
| Tolterodine Tartrate Er | 18 | $2,886 | $160 |
| Alfuzosin Hcl Er | 67 | $2,677 | $40 |
| Oxybutynin Chloride | 20 | $1,060 | $53 |
| Nitrofurantoin Mono-Macro | 43 | $864 | $20 |
| Bicalutamide | 21 | $828 | $39 |
| Terazosin | 22 | $725 | $33 |
| Sulfamethoxazole-Trimethoprim | 162 | $677 | $4 |
| Doxycycline Hyclate | 22 | $525 | $24 |
| Hydroxyzine | 22 | $456 | $21 |
| Amoxicillin-Clavulanate Potass | 41 | $397 | $10 |
| Bethanechol Chloride | 12 | $294 | $24 |
| Amitriptyline | 20 | $242 | $12 |
| Ciprofloxacin | 36 | $226 | $6 |
| Allopurinol | 11 | $130 | $12 |
| Fluconazole | 15 | $88 | $6 |
| Levofloxacin | 28 | $71 | $3 |
2020: 33 drugs
| Myrbetriq | 33 | $26,516 | $804 |
| Tamsulosin | 1,020 | $25,606 | $25 |
| Finasteride | 760 | $19,827 | $26 |
| Toviaz | 13 | $15,920 | $1,225 |
| Testosterone | 66 | $13,595 | $206 |
| Darifenacin Er | 20 | $10,217 | $511 |
| Estradiol | 53 | $9,441 | $178 |
| Premarin | 21 | $8,422 | $401 |
| Methenamine Hippurate | 42 | $8,319 | $198 |
| Trospium Chloride | 42 | $7,005 | $167 |
| Potassium Citrate Er | 38 | $6,723 | $177 |
| Silodosin | 31 | $5,993 | $193 |
| Oxybutynin Chloride Er | 88 | $5,637 | $64 |
| Testosterone Cypionate | 90 | $5,096 | $57 |
| Dutasteride | 71 | $4,500 | $63 |
| Tadalafil | 23 | $4,486 | $195 |
| Tolterodine Tartrate Er | 19 | $3,657 | $192 |
| Solifenacin | 35 | $3,616 | $103 |
| Cephalexin | 262 | $3,615 | $14 |
| Nitrofurantoin | 61 | $3,204 | $53 |
| Alfuzosin Hcl Er | 48 | $2,088 | $44 |
| Bicalutamide | 29 | $779 | $27 |
| Sulfamethoxazole-Trimethoprim | 167 | $584 | $3 |
| Oxybutynin Chloride | 17 | $577 | $34 |
| Doxycycline Hyclate | 26 | $473 | $18 |
| Nitrofurantoin Mono-Macro | 16 | $429 | $27 |
| Terazosin | 17 | $411 | $24 |
| Amoxicillin-Clavulanate Potass | 27 | $220 | $8 |
| Nystatin | 11 | $193 | $18 |
| Levofloxacin | 33 | $165 | $5 |
| Amitriptyline | 11 | $152 | $14 |
| Ciprofloxacin | 27 | $145 | $5 |
| Fluconazole | 16 | $85 | $5 |
2019: 34 drugs
| Myrbetriq | 32 | $23,565 | $736 |
| Tamsulosin | 904 | $22,880 | $25 |
| Vesicare | 29 | $21,301 | $735 |
| Toviaz | 24 | $19,769 | $824 |
| Finasteride | 645 | $17,230 | $27 |
| Premarin | 29 | $11,183 | $386 |
| Cialis | 23 | $9,484 | $412 |
| Trospium Chloride | 81 | $7,753 | $96 |
| Darifenacin Er | 12 | $6,634 | $553 |
| Methenamine Hippurate | 43 | $6,545 | $152 |
| Potassium Citrate Er | 52 | $6,458 | $124 |
| Oxybutynin Chloride Er | 95 | $6,122 | $64 |
| Estradiol | 28 | $6,074 | $217 |
| Tadalafil | 11 | $4,772 | $434 |
| Silodosin | 33 | $4,497 | $136 |
| Cephalexin | 316 | $4,084 | $13 |
| Dutasteride | 54 | $3,997 | $74 |
| Testosterone Cypionate | 82 | $3,788 | $46 |
| Tolterodine Tartrate Er | 28 | $3,775 | $135 |
| Solifenacin | 11 | $3,717 | $338 |
| Trospium Chloride Er | 11 | $3,106 | $282 |
| Nitrofurantoin | 57 | $2,392 | $42 |
| Bicalutamide | 43 | $1,405 | $33 |
| Alfuzosin Hcl Er | 40 | $1,131 | $28 |
| Oxybutynin Chloride | 26 | $878 | $34 |
| Testosterone | 11 | $877 | $80 |
| Sulfamethoxazole-Trimethoprim | 137 | $602 | $4 |
| Amitriptyline | 20 | $601 | $30 |
| Ciprofloxacin | 40 | $322 | $8 |
| Nitrofurantoin Mono-Macro | 20 | $313 | $16 |
| Amoxicillin-Clavulanate Potass | 30 | $308 | $10 |
| Terazosin | 14 | $213 | $15 |
| Levofloxacin | 26 | $200 | $8 |
| Nystatin | 11 | $141 | $13 |
2018: 32 drugs
| Vesicare | 69 | $45,352 | $657 |
| Tamsulosin | 1,009 | $28,788 | $29 |
| Myrbetriq | 52 | $22,434 | $431 |
| Rapaflo | 49 | $21,753 | $444 |
| Cialis | 44 | $19,150 | $435 |
| Finasteride | 698 | $15,459 | $22 |
| Toviaz | 26 | $13,625 | $524 |
| Premarin | 32 | $11,877 | $371 |
| Potassium Citrate Er | 53 | $8,991 | $170 |
| Darifenacin Er | 15 | $8,164 | $544 |
| Methenamine Hippurate | 48 | $7,555 | $157 |
| Oxybutynin Chloride Er | 115 | $6,733 | $59 |
| Trospium Chloride | 68 | $5,959 | $88 |
| Estradiol | 17 | $5,060 | $298 |
| Tolterodine Tartrate Er | 31 | $4,862 | $157 |
| Cephalexin | 404 | $4,718 | $12 |
| Dutasteride | 65 | $2,828 | $44 |
| Testosterone Cypionate | 66 | $2,733 | $41 |
| Trospium Chloride Er | 14 | $2,603 | $186 |
| Nitrofurantoin | 53 | $2,353 | $44 |
| Bicalutamide | 47 | $1,910 | $41 |
| Oxybutynin Chloride | 43 | $1,583 | $37 |
| Nitrofurantoin Mono-Macro | 33 | $1,172 | $36 |
| Alfuzosin Hcl Er | 33 | $1,001 | $30 |
| Bethanechol Chloride | 12 | $504 | $42 |
| Ciprofloxacin | 68 | $461 | $7 |
| Sulfamethoxazole-Trimethoprim | 101 | $450 | $4 |
| Terazosin | 17 | $304 | $18 |
| Amitriptyline | 15 | $260 | $17 |
| Amoxicillin-Clavulanate Potass | 22 | $197 | $9 |
| Levofloxacin | 28 | $161 | $6 |
| Nystatin | 18 | $161 | $9 |
2017: 35 drugs
| Vesicare | 88 | $47,554 | $540 |
| Tamsulosin | 1,037 | $32,278 | $31 |
| Cialis | 56 | $23,295 | $416 |
| Rapaflo | 58 | $20,780 | $358 |
| Myrbetriq | 51 | $16,585 | $325 |
| Finasteride | 644 | $14,021 | $22 |
| Estrace | 36 | $10,826 | $301 |
| Darifenacin Er | 26 | $8,736 | $336 |
| Trospium Chloride | 80 | $8,228 | $103 |
| Oxybutynin Chloride Er | 131 | $7,577 | $58 |
| Premarin | 21 | $7,222 | $344 |
| Potassium Citrate Er | 39 | $6,859 | $176 |
| Toviaz | 19 | $6,697 | $352 |
| Tolterodine Tartrate Er | 22 | $5,088 | $231 |
| Cephalexin | 453 | $4,879 | $11 |
| Methenamine Hippurate | 37 | $4,624 | $125 |
| Dutasteride | 49 | $4,609 | $94 |
| Dutasteride-Tamsulosin | 15 | $4,528 | $302 |
| Nitrofurantoin | 57 | $2,342 | $41 |
| Oxybutynin Chloride | 56 | $1,931 | $34 |
| Trospium Chloride Er | 15 | $1,842 | $123 |
| Testosterone Cypionate | 33 | $1,567 | $47 |
| Alfuzosin Hcl Er | 51 | $1,272 | $25 |
| Bicalutamide | 46 | $1,139 | $25 |
| Nitrofurantoin Mono-Macro | 33 | $806 | $24 |
| Ciprofloxacin | 82 | $590 | $7 |
| Sulfamethoxazole-Trimethoprim | 103 | $457 | $4 |
| Amitriptyline | 24 | $268 | $11 |
| Levofloxacin | 33 | $233 | $7 |
| Terazosin | 16 | $231 | $14 |
| Nystatin | 16 | $195 | $12 |
| Amoxicillin-Clavulanate Potass | 15 | $148 | $10 |
| Ampicillin Trihydrate | 12 | $110 | $9 |
| Fluconazole | 13 | $102 | $8 |
| Amoxicillin | 11 | $57 | $5 |
2016: 33 drugs
| Tamsulosin | 856 | $26,790 | $31 |
| Vesicare | 69 | $26,718 | $387 |
| Rapaflo | 57 | $19,491 | $342 |
| Elmiron | 12 | $13,057 | $1,088 |
| Finasteride | 559 | $12,275 | $22 |
| Estrace | 31 | $9,029 | $291 |
| Darifenacin Er | 23 | $8,789 | $382 |
| Dutasteride | 66 | $8,679 | $131 |
| Cialis | 25 | $8,206 | $328 |
| Oxybutynin Chloride Er | 135 | $6,816 | $50 |
| Toviaz | 22 | $6,480 | $295 |
| Premarin | 17 | $5,765 | $339 |
| Trospium Chloride | 68 | $5,406 | $79 |
| Tolterodine Tartrate Er | 31 | $5,367 | $173 |
| Myrbetriq | 15 | $4,334 | $289 |
| Cephalexin | 359 | $3,631 | $10 |
| Potassium Citrate Er | 20 | $3,029 | $151 |
| Methenamine Hippurate | 22 | $2,342 | $106 |
| Nitrofurantoin | 55 | $2,060 | $37 |
| Nitrofurantoin Mono-Macro | 28 | $990 | $35 |
| Alfuzosin Hcl Er | 36 | $955 | $27 |
| Ciprofloxacin | 119 | $910 | $8 |
| Oxybutynin Chloride | 19 | $773 | $41 |
| Testosterone Cypionate | 15 | $706 | $47 |
| Bicalutamide | 44 | $618 | $14 |
| Sulfamethoxazole-Trimethoprim | 86 | $445 | $5 |
| Amoxicillin-Clavulanate Potass | 23 | $259 | $11 |
| Terazosin | 15 | $237 | $16 |
| Levofloxacin | 25 | $147 | $6 |
| Fluconazole | 17 | $135 | $8 |
| Amitriptyline | 12 | $126 | $10 |
| Hydrocodone-Acetaminophen | 14 | $125 | $9 |
| Amoxicillin | 18 | $88 | $5 |
2015: 26 drugs
| Tamsulosin | 737 | $28,876 | $39 |
| Vesicare | 52 | $17,427 | $335 |
| Avodart | 54 | $17,186 | $318 |
| Rapaflo | 54 | $15,053 | $279 |
| Enablex | 34 | $13,796 | $406 |
| Finasteride | 513 | $8,608 | $17 |
| Jalyn | 17 | $6,664 | $392 |
| Tolterodine Tartrate Er | 25 | $5,721 | $229 |
| Cialis | 14 | $4,957 | $354 |
| Estrace | 20 | $4,662 | $233 |
| Toviaz | 18 | $4,068 | $226 |
| Trospium Chloride | 46 | $3,533 | $77 |
| Oxybutynin Chloride Er | 38 | $2,703 | $71 |
| Methenamine Hippurate | 17 | $2,242 | $132 |
| Cephalexin | 278 | $2,037 | $7 |
| Nitrofurantoin | 54 | $2,029 | $38 |
| Testosterone Cypionate | 18 | $1,454 | $81 |
| Alfuzosin Hcl Er | 45 | $1,082 | $24 |
| Bethanechol Chloride | 18 | $745 | $41 |
| Ciprofloxacin | 109 | $598 | $5 |
| Oxybutynin Chloride | 11 | $592 | $54 |
| Bicalutamide | 21 | $354 | $17 |
| Amoxicillin-Clavulanate Potass | 38 | $320 | $8 |
| Amitriptyline | 12 | $254 | $21 |
| Sulfamethoxazole-Trimethoprim | 42 | $205 | $5 |
| Hydrocodone-Acetaminophen | 11 | $83 | $8 |
2014: 26 drugs
| Avodart | 86 | $23,576 | $274 |
| Tamsulosin | 645 | $18,896 | $29 |
| Vesicare | 37 | $14,985 | $405 |
| Enablex | 38 | $10,925 | $288 |
| Rapaflo | 31 | $8,661 | $279 |
| Finasteride | 415 | $7,875 | $19 |
| Jalyn | 24 | $6,698 | $279 |
| Estrace | 34 | $6,372 | $187 |
| Trospium Chloride | 53 | $5,256 | $99 |
| Tolterodine Tartrate Er | 23 | $4,233 | $184 |
| Oxybutynin Chloride Er | 58 | $4,167 | $72 |
| Methenamine Hippurate | 28 | $3,586 | $128 |
| Trospium Chloride Er | 11 | $2,953 | $268 |
| Premarin | 11 | $2,325 | $211 |
| Nitrofurantoin | 44 | $1,976 | $45 |
| Cephalexin | 214 | $1,915 | $9 |
| Alfuzosin Hcl Er | 40 | $1,653 | $41 |
| Testosterone Cypionate | 18 | $1,526 | $85 |
| Ciprofloxacin | 134 | $692 | $5 |
| Amox Tr-Potassium Clavulanate | 35 | $387 | $11 |
| Terazosin | 16 | $319 | $20 |
| Bethanechol Chloride | 13 | $316 | $24 |
| Hydroxyzine | 12 | $260 | $22 |
| Sulfamethoxazole-Trimethoprim | 40 | $235 | $6 |
| Hydrocodone-Acetaminophen | 24 | $188 | $8 |
| Amitriptyline | 15 | $99 | $7 |
2013: 32 drugs
| Avodart | 85 | $18,492 | $218 |
| Tamsulosin | 584 | $17,784 | $30 |
| Detrol La | 31 | $11,220 | $362 |
| Finasteride | 422 | $11,122 | $26 |
| Vesicare | 39 | $10,757 | $276 |
| Enablex | 40 | $8,556 | $214 |
| Jalyn | 24 | $7,037 | $293 |
| Rapaflo | 24 | $5,896 | $246 |
| Estrace | 27 | $4,056 | $150 |
| Oxybutynin Chloride Er | 51 | $3,811 | $75 |
| Methenamine Hippurate | 21 | $3,274 | $156 |
| Trospium Chloride Er | 13 | $3,232 | $249 |
| Trospium Chloride | 24 | $2,917 | $122 |
| Alfuzosin | 45 | $2,845 | $63 |
| Nitrofurantoin | 55 | $2,612 | $47 |
| Urocit-K | 14 | $1,829 | $131 |
| Viagra | 11 | $1,826 | $166 |
| Cephalexin | 178 | $1,519 | $9 |
| Potassium Citrate | 13 | $1,068 | $82 |
| Testosterone Cypionate | 12 | $951 | $79 |
| Amox Tr-Potassium Clavulanate | 37 | $650 | $18 |
| Oxybutynin Chloride | 19 | $613 | $32 |
| Ciprofloxacin | 120 | $596 | $5 |
| Terazosin | 25 | $565 | $23 |
| Bicalutamide | 15 | $554 | $37 |
| Bethanechol Chloride | 25 | $532 | $21 |
| Hydroxyzine | 13 | $324 | $25 |
| Sulfamethoxazole-Trimethoprim | 43 | $224 | $5 |
| Levofloxacin | 21 | $202 | $10 |
| Hydrocodone-Acetaminophen | 12 | $86 | $7 |
| Fluconazole | 13 | $76 | $6 |
| Amitriptyline | 13 | $70 | $5 |
Money from drug and device companies
$38 in 2022
| 2022 | 1 | 1 | None | $38 |
| 2019 | 1 | 1 | None | $24 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Dornier MedTech America | Dornier Medtech | $38 | 1 payment
|
See the published payment
| Dornier MedTech America | Meals · 2022-12-31 | Dornier Medtech | $38 |
See earlier years (2019)
2019: $24
| Astellas Pharma US | Myrbetriq | $24 | 1 payment
|
Professional record
- NPI
- 1174529309
- Licence
- CA A56059California A56059: Current · expires 2027-08-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA ZZZ83789Z
- Taxonomy
- Urology (208800000X); Federal specialty code 174400000X (174400000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2005-06-22
- NPI last updated
- 2020-06-23
- NPI record certified
- 2020-06-23
This is when the NPI record was last certified, not a medical board exam.